Halozyme AI Stock Analysis
Want to see HALO full AI Analyst Report?
Halozyme (HALO) AI Stock Analysis
Halozyme
(NASDAQ:HALO)
The score is driven primarily by strong profitability and excellent cash generation, supported by a very upbeat earnings outlook with raised guidance. These positives are tempered by meaningful balance-sheet leverage/negative equity and weak near-term technical momentum despite oversold signals. Valuation is moderate and does not add a significant boost without a dividend yield.
Halozyme Key Performance Indicators (KPIs)
Revenue by SegmentAnalyzes income from different business areas, highlighting which segments drive growth and profitability, and revealing strategic focus areas.
Royalties have become the steady, fastest-growing engine for Halozyme, while product sales are increasing but remain lumpy and collaborative-agreement revenue spikes create quarter-to-quarter volatility. That shift points to a more asset-light, high-margin revenue mix driven by partner commercialization and milestones—good for cash conversion but raising dependence on a few partners and timing of launches/payments, so monitor partner concentration and milestone cadence for future upside or downside.
Halozyme (HALO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $10.94B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.24M
- Price to Earnings (P/E)
- 22.8
- Beta (1Y)
- 0.36
- Revenue Growth
- 45.03%
- EPS Growth
- -14.29%
- Country
- US
- Employees
- 423
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Halozyme Business Overview & Revenue Model
Company Description
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHAN...
How the Company Makes Money
Halozyme primarily makes money by licensing its ENHANZE® drug delivery technology to pharmaceutical and biotechnology partners and earning payments tied to those partners’ products. Key revenue streams typically include: (1) Royalties on net sales of...
Halozyme Earnings Call Summary
The call was strongly positive, supported by record revenue and royalty results, raised 2026 guidance, broad-based commercial product growth, expanding partner agreements, pipeline advancement and progress with Hypercon and Aerocon. The main negative items were higher operating expenses, adverse initial U.S. patent rulings, ongoing litigation and development and collaboration-revenue timing uncertainties, but these were outweighed by the reported operating momentum and growth opportunities.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Halozyme raised 2026 guidance to total revenue of $1.86 billion to $1.925 billion, representing growth of 33% to 38% over 2025; royalty revenue of $1.235 billion to $1.255 billion, representing growth of 42% to 45%; product sales of $525 million to $540 million; adjusted EBITDA of $1.24 billion to $1.29 billion, with adjusted EBITDA margin unchanged at approximately 67%; and non-GAAP diluted EPS of $8.75 to $9.05. The company expects 13 ENHANZE programs in clinical development by year-end 2026, Hypercon’s first clinical trial start in the first half of 2027, Aerocon new deal signings in 2027 and clinical entry in the second half of 2028, and up to 13 new products to launch between '29 and 2032, with development timelines of 4.5 to 5.5 years; it plans to provide 2027 guidance and an update on its long-range outlook when it reports fourth quarter results in February.
Halozyme Financial Statement Overview
Summary
Operating fundamentals are strong (high ~82% gross margin, ~27% net margin, and very strong TTM operating/free cash flow near $900M with positive FCF growth). The key risk is the balance sheet: debt is elevated (~$3.25B) and shareholder equity has turned slightly negative, which reduces flexibility and raises leverage risk if operating conditions weaken.
Income Statement
84Very PositiveBalance Sheet
34NegativeCash Flow
88Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.80B | 1.40B | 1.02B | 829.25M | 660.12M | 443.31M |
| Gross Profit | 1.48B | 1.17B | 855.91M | 636.89M | 520.81M | 361.90M |
| EBITDA | 805.64M | 573.05M | 656.54M | 451.95M | 315.51M | 259.04M |
| Net Income | 485.42M | 316.89M | 444.09M | 281.59M | 202.13M | 402.71M |
Balance Sheet | ||||||
| Total Assets | 3.47B | 2.53B | 2.06B | 1.73B | 1.84B | 1.10B |
| Cash, Cash Equivalents and Short-Term Investments | 1.07B | 142.82M | 596.07M | 336.00M | 362.79M | 740.92M |
| Total Debt | 3.25B | 2.14B | 1.51B | 1.50B | 1.51B | 876.67M |
| Total Liabilities | 3.53B | 2.48B | 1.70B | 1.65B | 1.67B | 907.48M |
| Stockholders Equity | -55.24M | 48.81M | 363.82M | 83.81M | 169.80M | 196.95M |
Cash Flow | ||||||
| Free Cash Flow | 885.88M | 644.59M | 468.37M | 373.28M | 235.30M | 297.98M |
| Operating Cash Flow | 898.27M | 651.56M | 479.06M | 388.57M | 240.11M | 299.44M |
| Investing Cash Flow | -786.38M | -545.81M | -262.72M | -96.91M | -487.00M | -406.29M |
| Financing Cash Flow | 499.30M | -85.17M | -218.86M | -407.99M | 362.37M | 77.86M |
Halozyme Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HALO, the sentiment is Negative. The current price of 95.97 is below the 20-day moving average (MA) of 116.96, below the 50-day MA of 114.04, and above the 200-day MA of 85.66, indicating a neutral trend. The MACD of -5.35 indicates Positive momentum. The RSI at 23.39 is Positive, neither overbought nor oversold. The STOCH value of 2.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HALO.
Halozyme Risk Analysis
Halozyme disclosed 40 risk factors in its most recent earnings report. Halozyme reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksHalozyme Peers Comparison
Overall Rating
ASND84Outperform
HALO69Neutral
LGND68Neutral
XERS66Neutral
ARWR46Neutral
IONS42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 84Outperform | $16.92B | 17.22 | 109.18% | ― | 93.79% | ― | |
| 69Neutral | $10.94B | 22.83 | 544.26% | ― | 45.03% | -14.29% | |
| 68Neutral | $5.88B | 112.70 | 5.22% | ― | 1.03% | 8.35% | |
| 66Neutral | $3.07B | -416.12 | -39.52% | ― | 38.37% | 63.43% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $6.08B | -8.39 | -170.58% | ― | -45.65% | -11471.36% | |
| 42Neutral | $4.49B | -8.07 | -120.44% | ― | -0.79% | -106.48% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HALO | Halozyme Therapeutics | 95.97 | 25.72 | 36.61% | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 42.99 | 4.02 | 10.32% | |
| IONS | Ionis Pharmaceuticals Inc. | 26.96 | -47.04 | -63.57% | |
| LGND | Ligand Pharmaceuticals Inc | 293.81 | 87.76 | 42.59% | |
| ASND | Ascendis Pharma A/S | 271.19 | 59.04 | 27.83% | |
| XERS | Xeris Pharmaceuticals | 16.80 | 9.71 | 136.95% |
Halozyme Corporate Events
Halozyme Therapeutics Adds James Daly to Board
NeutralOn September 28, 2026, Halozyme Therapeutics elected James Daly to its Board of Directors, placing him in the director class whose term expires at the 2029 annual meeting of stockholders. Daly was not initially assigned to any Board committee and wil...
Halozyme Raises $1.5 Billion via Convertible Notes Offering
PositiveOn September 22, 2026, Halozyme Therapeutics completed a $1.5 billion private offering of 1.50% Convertible Senior Notes due 2033, receiving about $1.47 billion in net proceeds after fees and expenses. The notes, sold to qualified institutional buyer...
Halozyme Prices Upsized $1.3 Billion Convertible Notes Offering
PositiveOn September 17, 2026, Halozyme Therapeutics, Inc. priced an upsized private offering of $1.3 billion in 1.50% convertible senior notes due October 1, 2033, with an option for initial purchasers to buy an additional $200 million, targeting qualified...
Halozyme announces $1.05B convertible notes offering
PositiveOn September 16, 2026, Halozyme Therapeutics, Inc. announced a proposed private offering of $1.05 billion in convertible senior notes due October 1, 2033, with an additional $150 million option for initial purchasers, aimed at qualified institutional...
Halozyme Appoints Dannielle Appelhans to Board of Directors
NeutralOn August 14, 2026, Halozyme Therapeutics elected Dannielle Appelhans to its Board of Directors, placing her in the director class with terms ending at the 2028 annual meeting of stockholders. She joins as a non-employee director with standard board...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
